Search results
Results from the WOW.Com Content Network
The certificate of pharmaceutical product (abbreviated: CPP) is a certificate issued in the format recommended by the World Health Organization (WHO), which establishes the status of the pharmaceutical product and of the applicant for this certificate in the exporting country; [1] it is often mentioned in conjunction with the electronic Common Technical Document (eCTD).
The MHRA has several independent advisory committees which provide the UK Government with information and guidance on the regulation of medicines and medical devices. There are currently eight such committees: [citation needed] Advisory Board on the Registration of Homeopathic Products; Herbal Medicines Advisory Committee; The Review Panel
Marketing Authorisation Application (MAA) is an application submitted by a drug manufacturer seeking marketing authorisation, that is permission to bring a medicinal product (for example, a new medicine or generic medicine) to the market.
A stringent regulatory authority is a regulatory authority which is: a) a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before ...
will maintain guidance documents on the format and content of applications to assist applicants in their preparation. (a) Application form. The applicant shall submit a completed and signed application form that contains the following: (1) The name and address of the applicant; the date of the application;
Download as PDF; Printable version; In other projects Wikidata item; ... MHRA may refer to: Organisations. Medicines and Healthcare products Regulatory Agency, UK;
European Union: In the EU, Good Clinical Practice is backed and regulated by formal legislation contained in the Clinical Trial Regulation (Officially Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC). [3]
The scheme provides forms that allow members of the public to report suspected side effects, as well as health professionals. [ 6 ] NHS Digital publishes an information standard DCB1582 for electronic submission of adverse reactions by IT systems [ 7 ] (until 2014, this was ISB 1582 from the Information Standards Board). [ 8 ]